Reduced risk of gastrointestinal bleeding associated with eupatilin in aspirin plus acid suppressant users: nationwide population-based study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Mucoprotective agents, such as eupatilin, are often prescribed to prevent gastrointestinal (GI) bleeding in addition to an acid suppressant despite the absence of a large-scale study. We evaluated the additional effect of eupatilin on the prevention of GI bleeding in both the upper and lower GI tract in concomitant aspirin and acid suppressant users using the nationwide database of national claims data from the Korean National Health Insurance Service (NHIS). Methods: An aspirin cohort was constructed using the NHIS claims data from 2013 to 2020. Patients who manifested with hematemesis, melena, or hematochezia were considered to have GI bleeding. A Cox proportional hazards regression model was used to determine the risk factors for GI bleeding associated with the concomitant use of GI drugs and other covariates among aspirin users. Results: Overall, a total of 432,208 aspirin users were included. The concurrent use of an acid suppressant and eupatilin (hazard ratio [HR] = 0.85, p = 0.016, vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding. Moreover, a more than 3-month duration (HR = 0.88, p = 0.030) of acid suppressant and eupatilin prescription (vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding. Conclusions: Eupatilin administration for ≥ 3 months showed additional preventive effect on GI bleeding in concomitant aspirin and acid suppressant users. Thus, cotreatment with eupatilin with a duration of 3 months or longer is recommended for reducing GI bleeding among aspirin plus acid suppressant users.
Abstract
Background/Aims: Mucoprotective agents, such as eupatilin, are often prescribed to prevent gastrointestinal (GI) bleeding in addition to an acid suppressant despite the absence of a large-scale study. We evaluated the additional effect of eupatilin on the prevention of GI bleeding in both the upper and lower GI tract in concomitant aspirin and acid suppressant users using the nationwide database of national claims data from the Korean National Health Insurance Service (NHIS). Methods: An aspirin cohort was constructed using the NHIS claims data from 2013 to 2020. Patients who manifested with hematemesis, melena, or hematochezia were considered to have GI bleeding. A Cox proportional hazards regression model was used to determine the risk factors for GI bleeding associated with the concomitant use of GI drugs and other covariates among aspirin users. Results: Overall, a total of 432,208 aspirin users were included. The concurrent use of an acid suppressant and eupatilin (hazard ratio [HR] = 0.85, p = 0.016, vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding. Moreover, a more than 3-month duration (HR = 0.88, p = 0.030) of acid suppressant and eupatilin prescription (vs. acid suppressant only) was a statistically significant preventive factor for GI bleeding. Conclusions: Eupatilin administration for ≥ 3 months showed additional preventive effect on GI bleeding in concomitant aspirin and acid suppressant users. Thus, cotreatment with eupatilin with a duration of 3 months or longer is recommended for reducing GI bleeding among aspirin plus acid suppressant users.
참고문헌 (35)
- Go AS, "Heart disease and stroke statistics--2013 update: a report from the American Heart Association", Circulation, 127, pp.e6~e245 (2013)
- Antithrombotic Trialists’(ATT)Collaboration, "Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials", Lancet, 373, pp.1849~1860 (2009)
- Luepker RV, "Population trends in aspirin use for cardiovascular disease prevention 1980-2009 : the Minnesota Heart Survey", J Am Heart Assoc, 4, pp.e002320~ (2015)
- Kang DO, "Cardiovascular and bleeding risks associated with nonsteroidal anti-inflammatory drugs after myocardial infarction", J Am Coll Cardiol, 76, pp.518~529 (2020)
- Selak V, "Annual risk of major bleeding among persons without cardiovascular disease not receiving antiplatelet therapy", JAMA, 319, pp.2507~2520 (2018)
- Lin KJ, "Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy", Gastroenterology, 141, pp.71~79 (2011)
- Lai KC, "Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use", N Engl J Med, 346, pp.2033~2038 (2002)
- Graham DY, "Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs:results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole", Arch Intern Med, 162, pp.169~175 (2002)
- Abraham NS, "National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs", Gastroenterology, 129, pp.1171~1178 (2005)
- Lanas A, "Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding", Gastroenterology, 103, pp.862~869 (1992)
- Strate LL, "Early predictors of severity in acute lower intestinal tract bleeding", Arch Intern Med, 163, pp.838~843 (2003)
- Chen WC, "The risk of lower gastrointestinal bleeding in low-dose aspirin users", Aliment Pharmacol Ther, 45, pp.1542~1550 (2017)
- Chan FK, "Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin", Gastroenterology, 152, pp.105~110 (2017)
- Nadatani Y, "Incidence and risk factors of gastrointestinal bleeding in patients on lowdose aspirin therapy after percutaneous coronary intervention in Japan", Scand J Gastroenterol, 48, pp.320~325 (2013)
- Miyake K, "Proton pump inhibitors are associated with lower gastrointestinal tract bleeding in low-dose aspirin users with ischaemic heart disease", Dig Liver Dis, 47, pp.757~762 (2015)
- Lué A, "Protons pump inhibitor treatment and lower gastrointestinal bleeding : balancing risks and benefits", World J Gastroenterol, 22, pp.10477~10481 (2016)
- Watanabe T, "Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol : a pilot study", Clin Gastroenterol Hepatol, 6, pp.1279~1282 (2008)
- Bianchi Porro G, "Side effects of anti-ulcer prostaglandins : an overview of the worldwide clinical experience", Scand J Gastroenterol Suppl, 164, pp.224~229 (1989)
- Chan FK, "Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen", N Engl J Med, 344, pp.967~973 (2001)
- Taha AS, "Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin(FAMOUS) : a phase III, randomised, double-blind, placebo-controlled trial", Lancet, 374, pp.119~125 (2009)
- Kwok CS, "Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics : meta-analysis", Am J Gastroenterol, 107, pp.1011~1019 (2012)
- García Rodríguez LA, "Use of acid-suppressing drugs and the risk of bacterial gastroenteritis", Clin Gastroenterol Hepatol, 5, pp.1418~1423 (2007)
- Khalili H, "Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors : a prospective cohort study", BMJ, 344, pp.e372~ (2012)
- Hoorn EJ, "A case series of proton pump inhibitor-induced hypomagnesemia", Am J Kidney Dis, 56, pp.112~116 (2010)
- Choi SM, "Gastroprotective effects of DA-6034, a new flavonoid derivative, in various gastric mucosal damage models", Dig Dis Sci, 52, pp.3075~3080 (2007)
- Huh K, "Inhibitory effects of DA-9601on ethanol-induced gastrohemorrhagic lesions and gastric xanthine oxidase activity in rats", J Ethnopharmacol, 88, pp.269~273 (2003)
- Kim JS, "In vivo gastric residence and gastroprotective effect of floating gastroretentive tablet of DA-9601, an extract of Artemisia asiatica, in beagle dogs", Drug Des Devel Ther, 10, pp.1917~1925 (2016)
- Seol SY, "DA-9601 for erosive gastritis : results of a double-blind placebo-controlled phase III clinical trial", World J Gastroenterol, 10, pp.2379~2382 (2004)
- Kim TJ, "Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users", Sci Rep, 9, pp.11696~ (2019)
- Kim SH, "Changes in performance of small bowel capsule endoscopy based on nationwide data from a Korean Capsule Endoscopy Registry", Korean J Intern Med, 35, pp.889~896 (2020)
- Lee HS, "Association between eupatilin and reduction in small bowel bleeding in aspirin users and aspirin plus acid suppressant users", Korean J Intern Med, 38, pp.484~492 (2023)
- Edogawa S, "Current topics of strategy of NSAID-induced small intestinal lesions", Digestion, 92, pp.99~107 (2015)
- Oh TY, "Oxidative damages are critical in pathogenesis of reflux esophagitis : implication of antioxidants in its treatment", Free Radic Biol Med, 30, pp.905~915 (2001)
- Choi EJ, "Eupatilin protects gastric epithelial cells from oxidative damage and down-regulates genes responsible for the cellular oxidative stress", Pharm Res, 25, pp.1355~1364 (2008)
- Jung YS, "Impact of proton pump inhibitors on the risk of small bowel or colorectal bleeding : A systematic review and meta-analysis", United European Gastroenterol J, 11, pp.861~873 (2023)